Our API - EU Portfolio** consists of the following:
Therapeutic Category Name of API Regulatory Status
Anti-cancer Bortezomib --
Busulfan --
Bicalutamide --
Cabazitaxel * --
Carboplatin --
Docetaxel Trihydrate --
Docetaxel anhydrous --
Gemcitabine HCl --
Gemcitabine HCI (Alternate process) --
Irinotecan Hydrochloride Trihydrate --
Letrozole --
Oxaliplatin --
Paclitaxel Semi-synthetic --
Pemetrexed Diacid --
Bendamustine Hydrochloride --
Azacitidine @ --
Reversal of neuromuscular blockade Sugammadex Sodium * --
Anesthetics Bupivacaine Hydrochloride -- @
Levobupivacaine Hydrochloride --
Ropivacaine Hydrochloride Monohydrate --
Ropivacaine Hydrochloride Anhydrous * --

Granted   *Filed   @ To be filed – Not filed

**The buyer / customer should make their independent evaluation of the patent scenario for their respective markets, in respect of the API/formulations bought from Fresenius Kabi Oncology Limited, and they shall be solely and exclusively responsible for all patent related liabilities including any litigation by third party.

Fresenius Kabi Oncology Ltd. do not intend to manufacture any product commercially until there is a valid IP. Listing of product shall not be construed in any way that Fresenius Kabi Oncology has violated any IP laws of the land.


© All Copyright Reserved | Fresenius Kabi Oncology Limited 2012-2018